Hanmi Pharm. Co., Ltd.

Hanmi Holdings Co., Ltd.

Id Biochem, Inc.

Hanmi Science Co., Ltd.

Se-Chang Kwon

Gwan-Sun Lee

Sung-Youb Jung

Sung-Min Bae

Ki-Doo Choi

Young-Min Kim

Sung Youb Jung

Dae Hae Song

Dae-Jin Kim

Jin Sun Kim

Woo-Hyuk Choi

Jin Hwan Shin

Jay-Do Choi

Hoon Shin

Cha-Soon Kim

Pyeong-uk Park

Chang-Ki Lim

Seong-Nyun Kim

Hak-Sun Jang

Pyeong-Uk Park

A method for preparing high-purity polyethyleneglycol-alkylenealdehydes and derivatives thereof is provided.

Method for preparing high-purity polyethyleneglycol aldehyde derivatives

A protein conjugate having a prolonged in vivo half-life of a physiological activity, comprising i) a physiologically active polypeptide, ii) a non-peptidic polymer, and iii) an immunoglobulin, is useful for the development of a polypeptide drug due to the enhanced in vivo stability and prolonged half-life in blood, while reducing the possibility of inducing an immune response.

Physiologically active polypeptide conjugate having prolonged in vivo half-life

Disclosed is a method for the mass production of a monomeric or dimeric immunoglobulin Fc region, free of initial methionine residues, using a recombinant expression vector comprising a nucleotide sequence coding for a recombinant immunoglobulin Fc region comprising an immunoglobulin Fc region linked at the N-terminus thereof to an immunoglobulin Fc region via a peptide bond.

Method for the mass production of immunoglobulin Fc region deleted initial methionine residues

A modified human granulocyte-colony stimulating factor (hG-CSF) is produced by culturing a microorganism transformed with an expression vector comprising a gene encoding a modified hG-CSF to produce and secrete the modified hG-CSF to periplasm, said modified hG-CSF being obtained by replacing at least one of the 1st, 2nd, 3rd and 17th amino acids of wild-type hG-CSF (SEQ ID NO: 2) with other amino acid.

Modified human granulocyte-colony stimulating factor and process for producing same

Disclosed in this invention are an expression vector for the secretive production of human interferon alpha (hIFN&#x3b1;) comprising a polynucleotide encoding a modifiedthermostable enterotoxin II signal sequence and a polynucleotide encoding hIFN&#x3b1; ligated to the 3'-end thereof; a microorganism transformed with the expression vector; and a process for secretively producing human interferon by culturing the microorganism, the process being capable of secreting a soluble form of active hIFN&#x3b1;, which does not contain an additional methionine residue at its N-terminal, into the periplasm of ancell.

Expression and secretion vector for human interferon alpha and process for producing human interferon alpha by employing same

A heterologous protein is produced by: (i) culturing a microorganism transformed with an expression vector comprising a gene encoding a modified enterotoxin II signal peptide fused with the heterologous protein to produce and secrete the heterologous protein to periplasm, the modified enterotoxin II signal peptide being obtained by replacing at least one of the 2nd, 4th, 5th, 12th, 20th, and 22nd amino acids of enterotoxin II signal peptide of the following amino acid sequence (SEQ ID NO: 1) with another amino acid, with the proviso that at least one of the 2nd and 4th amino acid of the modified peptide is lysine; and (ii) recovering the heterologous protein from the periplasm.

Modified E. coli enterotoxin II signal peptide and a microorganism expressing a fusion protein of a said peptide and a heterologous protein

Growing community of inventors

Seoul, South Korea

Se-Chang Kwon